The purpose of this study is to determine the efficacy and safety of topic ketorolac in treatment for center point thickness secondary to panphotocoagulation in proliferative diabetic retinopathy.
Panphotocoagulation is the standard treatment for proliferative diabetic retinopathy during 3 to 4 sessions within 2 weeks. This treatment reduces the incidence of severe visual loss in the long term. Nonetheless, it induces macular thickness that delays the conclusion of the treatment. This delay could coincide with vitreous hemorrhage which, in turn, may limit additional photocoagulation. Topic ketorolac could limit the inflammatory reaction cause by panphotocoagulation and produce early benefits in the patient.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
44
Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation
Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation
Virgilio Lima Gomez
Mexico City, Mexico City, Mexico
center subfield mean thickness using Stratus OCT measured in microns
Time frame: baseline, 24, 48 and 168 hours after treatment
center point thickness using Stratus OCT, measured in microns
Time frame: baseline, 24, 48 and 168 hours after treatment
macular volume using Stratus OCT, measured in cubic millimeters
Time frame: baseline, 24, 48 and 168 hours after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.